Evidence map›Paper›PMID 38697305›Full record

ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2024

Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes.

Anastasia-Stefania Alexopoulos, Alice Parish, Maren Olsen, Bryan C Batch, Cynthia A Moylan, Matthew J Crowley

Abstract read
In one paragraph

Article in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anastasia-Stefania AlexopoulosDivision of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham VA Medical Center, Durham, North Carolina. Electronic address: asa61@duke.edu.
Alice ParishDepartment of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
Maren OlsenCenter of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham VA Medical Center, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
Bryan C BatchDivision of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Division of Endocrinology, Department of Medicine, Durham VA Medical Center, Durham, North Carolina.
Cynthia A MoylanDivision of Gastroenterology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Division of Gastroenterology, Department of Medicine, Durham VA Medical Center, Durham, North Carolina.
Matthew J CrowleyDivision of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, North Carolina; Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham VA Medical Center, Durham, North Carolina.

Funding

Institutional Career Development CoreKL2TR002554 · NCATS · DUKE UNIVERSITY · PI SVETKEY, LAURA P · 2018 to 2022
$8.2M
NCATS NIH HHS KL2 TR002554
6 · The paper itself

Abstract

objectiveTo assess frequency of evidence-based management (EBM) of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes (T2D), and to examine for racial/ethnic disparities in the receipt of EBM.

methodsWe conducted a cross-sectional analysis of patients with T2D and presumptive MASLD in an academic health care system between 2019 and 2021. Presumptive MASLD was defined as at least 1 alanine aminotransferase value ≥30 U/L with exclusions for alcohol overuse, viral hepatitis, liver transplantation, chemotherapy use, and liver disease other than MASLD. We calculated the proportion of patients receiving EBM, defined as a composite of liver ultrasound, transient elastography, or hepatology evaluation. We also examined the association between race/ethnicity and EBM via a logistic regression model.

resultsOur sample included 6532 patients; mean age was 58.0 (SD 13.1), 41.7% were female and 3.9%, 26.6%, 58.7%, and 5.8% were of Latino/a/x ethnicity, non-Latino (NL) Black race, NL White race, and NL Asian race, respectively. Rates of EBM were low overall (11.5%), with lower odds of EBM in NL Black versus NL White patients (adjusted odds ratio 0.75; 95% confidence interval 0.59, 0.96). Odds of hepatology evaluation and placement of MASLD diagnosis codes were also lower in NL Black versus NL White patients.

conclusionRacial disparities exist in the receipt of EBM among patients with T2D and presumptive MASLD. These findings highlight the need for research to identify drivers of disparities, and to support development of clinical interventions that equitably facilitate EBM of MASLD in patients with T2D.

Indexed as

Diabetes Mellitus, Type 2Healthcare DisparitiesAdultAgedCross-Sectional StudiesFatty LiverFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver Diseaseevidence-based managementmetabolic dysfunction-associated fatty liver diseaseracial disparitiestype 2 diabetes

Identifiers

PMID38697305
PMCPMC11223982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.